Novel cardiovascular biomarkers and implications for clinical trials

Abstract

In summary, certain novel biomarkers and noninvasive imaging modalities might turn out to be highly sensitive, specific and reproducible in nearly all patients with cardiovascular disease. If so, they could be used to prioritize, simplify and modulate expensive clinical prevention trials of hard cardiovascular endpoints involving thousands of patients. © 2006 Nature Publishing Group.